Heart failure & cardiomyopathies
Cardiovascular risks of continuing vs. initiating non-steroidal anti-inflammatory drugs (NSAIDs) after first-time myocardial infarction or heart failure: a nationwide cohort study
Authors' conclusion
NSAID initiators were more susceptible to adverse cardiovascular outcomes after first-time MI or HF than continuing users.
Study context
- Population
- Patients with first-time myocardial infarction (MI) or heart failure (HF), 1996–201897,966 NSAID users
- Participants
- 273,682 patients
- Exposure
- NSAID users vs non-users
- Outcome
- Composite of:
- New MI
- HF admission
- All-cause death
- Follow-up
- From 30 days after index discharge
Methodological detailsnationwide health registries, Cox regression
- Nationwide health registries
- Cox regression
Main finding
As reported in the abstract
Each group vs non-usersHazard ratio (95% CI)
NSAID usersall NSAID users
1.25(1.23–1.27)
Initiating users
1.39(1.36–1.41)
Continuing users
1.03(1.00–1.07)
Observational data: associations, not effects.
Further findings
Composite outcome by individual NSAID, continuing users vs non-users
- Continuing users, diclofenac: HR
- 1.11 (95% CI 1.05-1.18)
- No association for ibuprofen or naproxen among continuing users
Composite outcome by individual NSAID, initiators vs non-users
- Initiators, diclofenac: HR
- 1.63 (CI 1.57-1.69)
- Initiators, ibuprofen: HR
- 1.31 (CI 1.27-1.35)
- Initiators, naproxen: HR
- 1.19 (CI 1.08-1.31)
MI and HF patients, individual components of composite, sensitivity analyses
- Results consistent for MI and HF patients, individual components of the composite outcome and various sensitivity analyses
Original publication
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. Published 29 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →